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ABSTRACT 
The heat pain threshold was assessed in 32 healthy participants after a mild burn on the dorsal 
surface of each hand, after injection of an opioid antagonist (80 µg naloxone) or vehicle alone 
(0.2 mL saline) into the burnt skin of one hand, and after repeated painful immersion of this 
hand in cold water for up to 180 s. We hypothesized that sensitivity to heat would decrease at 
the burn-injured site after the immersions, due to local release of opioids into the burnt skin. 
Naloxone augmented cold-induced pain during the immersions in participants who tolerated 
the longest immersions, implying that release of endogenous opioids suppressed cold-pain. 
After the immersions, sensitivity to heat decreased at the burn-injured site in the immersed 
hand, but naloxone did not block this effect. Instead, naloxone altered sensitivity to heat in 
unburnt skin, implying that thermal hyperalgesia at sites of burn injury masked the 
modulatory effects of opioids. In particular, naloxone blocked a decrease in sensitivity to heat 
at an unburnt site on the contralateral hand of participants who tolerated the longest 
immersions, consistent with central or systemic opioid release. Naloxone reduced sensitivity 
to heat at unburnt sites in participants who tolerated medium-length immersions, suggesting 
that an increase in systemic or central opioid activity evoked thermal hyperalgesia in this 
group. In addition, in a small group of participants who tolerated only brief immersions, 
naloxone blocked decreases in sensitivity to heat at an unburnt site in the immersed hand. 
These findings suggest that repeated painful immersions trigger local opioid release in 
participants who tolerate only brief immersions, and elicit central or systemic opioid release 
in participants who tolerate longer immersions.  
Perspective: This article demonstrates that repeated immersion of the hand in painfully cold 
water increases opioid activity, and that the increase in opioid activity exerts multiple 
opposing effects on sensitivity to heat. Individual differences in the response to opioids might 
contribute to individual differences in pain tolerance.  
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Introduction 
Endogenous opioids, released within the central nervous system and from the adreno-
hypophyseal axis, inhibit pain during stress.24,39 This stress-induced analgesia may have 
evolved to increase the likelihood of survival during times of physical threat, thereby 
facilitating self-defense and avoidance of further injury.1,38 In rodents, stressful procedures 
such as electric shocks and cold-water swims can evoke central opioid-mediated 
analgesia.34,35 In humans, the opiate receptor antagonist naloxone has been shown to block 
analgesia following cognitive stress,3 anticipation of painful foot shock,41-43 and the 
immersion of one foot in ice-water.20 Naloxone also augmented thermal hyperalgesia induced 
by the topical application of capsaicin.2 Although such findings indicate that endogenous 
opioids contribute to analgesia, the site of action is uncertain because the dose of naloxone 
used in these studies was sufficient to produce substantial blockade of opiate receptors both 
within and outside the central nervous system.  
A component of endogenous opioid analgesia may be mediated peripherally. In rats, the 
withdrawal threshold to pressure applied to an inflamed paw increased after an ice-water 
swim, due to local release of β-endorphin from immune cells.26,27,31 In humans, synovial fluid 
obtained during knee surgery contained immune cells, many holding β-endorphin.33 The intra-
articular injection of naloxone immediately following knee surgery increased pain ratings, 
scores on the McGill pain questionnaire and consumption of analgesics,33 consistent with 
peripheral opioid analgesia. 
We recently found evidence of peripheral opioid analgesia in an experimental burn model 
in humans.29 In this model, naloxone (80 µg) was injected subcutaneously at a site of mild 
burn injury in the forearm of 24 volunteers, and saline was injected at another burn site in the 
other forearm. The naloxone pre-treatment blocked the local antihyperalgesic effect of 10 µg 
fentanyl but did not block the antihyperalgesic effect of fentanyl injected contralaterally, 
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consistent with local opioid receptor blockade.  
The primary aim of the present study was to investigate the effect of repeatedly 
immersing one hand in cold water on heat-pain sensitivity at sites of burn injury (intended to 
evoke an inflammatory response that facilitated peripheral opioid analgesia) and elsewhere in 
both hands. Analgesia develops following the repeated immersion of the hand in cold water,37 
but the mechanism of this analgesia is unknown. The pain and distress evoked by the cold-
water immersions might activate opioid-sensitive pain modulation processes in the central 
nervous system.3,20,34,35,41-43 In addition, cold-water immersions could accelerate the local 
release of endogenous opioids from immune cells.26-28,30-33 If so, this should reduce sensitivity 
to noxious stimulation in the immersed hand relative to the contralateral hand. Moreover, a 
higher concentration of immune cells at the site of burn injury might augment local opioid 
analgesia. To investigate this possibility, 80 µg naloxone or saline was injected 
subcutaneously at the burn-injured site in the immersed hand.  
A second aim was to investigate effects of opioid blockade on pain tolerance during the 
cold water immersions. Naloxone augments shock-induced pain and cortical evoked 
potentials in pain-insensitive individuals, but reduces pain and evoked potentials in pain-
sensitive people.6 Thus, we expected that the hyperalgesic effects of opioid blockade would be 
greatest in pain-tolerant participants. 
Method 
Participants 
The sample consisted of 17 men and 15 women aged between 17 and 39 years (median 
age 19 years). They were informed that the experiment aimed to investigate the effect of the 
opiate antagonist naloxone on pain sensitivity induced by a mild burn and repeated immersion 
of their hand in cold water. Each participant received A$20 for time spent and provided 
informed consent for the procedures, which were approved by the Ethics Committee of the 
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University of Western Australia.  
Apparatus and Procedures 
The sequence of procedures is summarized in Table 1. Participants attended the 
laboratory on two occasions, separated by 4 to 7 days. The temperature of the laboratory 
ranged between 20 and 23ºC. On each occasion, the 10-mm diameter probe of a 
thermocouple-controlled cautery unit, heated to 48oC, was applied with a force of 
approximately 1 N in hairy skin over the first dorsal interosseous muscle of each hand for 120 
s to produce a mild burn.11 Thirty minutes later, heat-pain thresholds (HPT) were measured at 
the burn site and at a control site 2-5 cm laterally from each burn site on both hands. Although 
the burn sites were approximately the same on each occasion, the HPT after the burn did not 
differ systematically from the first to the second occasion, irrespective of whether naloxone or 
saline was injected at the site of burn injury on the first occasion. Thus, effects of the burn and 
injection on the HPT appeared to have dissipated by the second occasion.  
The HPT was determined by directing radiant heat from a halogen globe through a lens 
and circular aperture (1.1 cm in diameter) onto the skin. Skin temperature was measured by a 
thermistor which was positioned under an aluminum shield in the centre of the aperture. The 
arm of the lamp was adjusted to allow the thermistor to touch the skin lightly without 
transferring the weight of the lamp. Skin temperature was held at a baseline of 35.6ºC for 10 s 
and then increased linearly at 0.5ºC per second. Participants switched the heat lamp off when 
they first felt pain (the HPT) or the heat lamp was automatically switched off when the 
temperature reached 47oC. Two HPT estimates were conducted at each site, with a third 
administered if the first two differed by more than 2ºC. Participants wore an eye-mask during 
sensory testing to minimize visual cues that might otherwise have affected the HPT. 
After the post-burn assessment, 0.2 mL 0.9% saline, with or without 80 µg naloxone 
hydrochloride, was injected subcutaneously into one of the burn sites (the dominant hand on 
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50% of occasions). The injection was administered double-blind, and half the participants 
received naloxone in the first session. The HPT was measured again starting five minutes 
after the injection.  
Skin temperature was then measured with an insulated thermistor at the four test sites, 
and participants began a series of immersions of the hand that had been injected with 
naloxone or saline. On each trial, participants immersed their hand up to the wrist in stirred 
2oC water for as long as they could or until three minutes had elapsed. The immersion 
duration at pain onset and the total immersion duration (the immersion pain tolerance) were 
recorded for each trial. Upon removal of the hand, participants gave a verbal rating of the 
maximum pain experienced during the immersion, ranging from 0 (no pain) to 10 (worst pain 
ever). The hand remained out of the water for 20 s and was then re-immersed. Each 
participant completed six to ten trials. Trials were discontinued when one of the following 
criteria37 was met: (1) at least six trials were completed and cumulative immersion time across 
the trials was at least 10 minutes; (2) at least six trials were completed and immersion time 
was three minutes on three consecutive trials; or (3) ten trials were completed. 
Upon completion of the cold-water immersions, the immersed hand was placed in warm 
water at 33 + 1ºC for 1-2 minutes and was held in front of a fan heater at the maximum 
comfortable temperature for a further 2-3 minutes. The cold-induced pain subsided rapidly 
during re-warming. Warming was discontinued when skin temperature approximated pre-
immersion levels. The HPT was then re-measured two more times, with a 5-minute interval 
between the first and the second measure.  
Data are displayed as means (M) + standard error of the mean. Experimental effects were 
investigated in repeated measures analyses of variance and with Pearson’s correlation 
coefficient (r). The multivariate solution was employed for repeated measures factors with 
more than two levels. 
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RESULTS 
Changes in skin temperature 
 
Mean skin temperature was greater at the burnt sites than the unburnt sites (M [burnt] = 
31.3 + .3 oC, M [unburnt] = 30.8 + .3 oC; F (1,30) = 44.5, p <0.001), but did not differ 
between the naloxone and saline sessions, between the immersed and non-immersed hand, or 
from before to after the immersions (Table 2). Thus, the inflammatory response at the burn 
sites increased skin temperature, and warming the hand after the immersions returned skin 
temperature to pre-immersion levels.  
Effect of naloxone on pain during the immersions 
As opioid release during the immersions might influence pain sensitivity, we examined 
the effect of the opioid antagonist naloxone on pain during the immersions. The average 
duration of immersion correlated strongly across sessions, r (30) = .69, p < .001 (Figure 1A) 
but, nevertheless, was shorter in the naloxone session than the saline session in the most pain-
tolerant participants, r (30) = .42, p < .05 (Figure 1B). To investigate this further, we allocated 
participants to three groups defined by their immersion duration scores in the saline session: 
those with a mean immersion duration per trial of less than 35 s (range 9-34 s), who were 
regarded as pain-intolerant (N = 7; lower 22% of the distribution), those with a mean 
immersion duration per trial of 57-128 s (mid-range; N = 16; middle 50% of the distribution), 
and those with an immersion duration of 142-180 s (pain-tolerant; N = 9; upper 28% of the 
distribution) (Figure 1B). The average duration of immersion was greater in the saline session 
than the naloxone session in pain-tolerant participants (168 + 5 s versus 132 + 16 s, t (8) = 
2.89, p < .05) but did not differ between the saline and naloxone sessions in the other two 
groups. Sex, age, and mean HPT in burnt and unburnt skin before the immersions were 
similar in each of the three groups (Table 3). 
The effect of naloxone on the immersion duration at pain onset, pain tolerance, and on 
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cold-pain ratings was investigated over the first six immersions, which were completed by all 
participants. The time taken to reach the pain threshold increased over the first six immersions 
(linear component of the Trials main effect: F (1,29) = 12.2, p < .01), primarily in mid-range 
and pain-tolerant participants (Figure 2A-C), and was greater by the sixth trial of the saline 
session than the naloxone session in pain-tolerant participants (main effect for Drug: F(1,29) 
= 5.51, p < .05; linear component of the Trials x Drug interaction: F (1,29) = 5.23, p < .05; 
Figure 2C). As shown in Figure 2D-F, cold-pain tolerance also increased over the first six 
trials in mid-range and pain-tolerant participants (linear component of the Trials main effect: 
F (1,29) = 7.37, p < .05), and was greater in the saline than the naloxone session in pain 
tolerant participants during Trials 2-4 (Pain Group x Drug interaction: F (2,29) = 5.21, p < 
.05; quadratic component of the Pain Group x Drug x Trials interaction: F (2,29) = 4.08, p < 
.05; Figure 2F). Pain ratings over the first six immersions are presented in Figure 2G-I. 
Ratings decreased during the last few immersions in pain tolerant participants (quadratic 
component of the Trials main effect F (1,29) = 7.16, p < .01; Figure 2I), and were greater 
during Trials 3 and 4 of the naloxone session than the saline session in this group (Pain Group 
x Drug interaction: F (2,29) = 4.18, p < .05). 
These findings suggest that opioid release was greatest in pain-tolerant participants 
during the cold-water immersions. Thus, changes in sensitivity to heat after the immersions 
were explored in relation to individual differences in cold pain tolerance in analyses of 
variance. The results of these analyses are presented below.  
Effect of the injections and the immersions on the HPT  
Preliminary analyses indicated that the HPT was lower at the burnt sites than the unburnt 
sites 30 minutes after the burns (M [burnt] = 41.1 + 0.35 oC; M [unburnt] = 42.5 + 0.46 oC; t 
(31) = 7.04, p < .001), and that thermal hyperalgesia persisted at the burn sites after the cold 
water immersions (Figure 3A-B).  
  
- 9 - 
Changes in the HPT from before to after the injections were investigated in Drug (saline, 
naloxone) x Phase (before versus after the injections) x Injection Site (ipsilateral, 
contralateral) x Pain Group (pain-intolerant, mid-range, pain-tolerant) repeated-measures 
analyses of variance, separately for burnt and unburnt sites. None of the main effects or 
interactions was significant, indicating that neither the saline nor the naloxone injection had 
any immediate effect on the HPT and implying that opioid release did not affect sensitivity to 
heat before the cold-water immersions. 
Changes in the HPT from before to after the immersions were investigated in Drug 
(saline, naloxone) x Immersion (immersed, non-immersed) x Phase (before immersions, and 
two measures after the immersions) x Pain Group (pain-intolerant, mid-range, pain-tolerant) 
repeated-measures analyses of variance. To simplify Phase effects, each measure after the 
immersions was compared with the pre-immersion measure in planned contrasts.  
Burnt sites. The HPT increased at the burnt site in the immersed hand immediately after 
the immersions, but not at the burnt site in the non-immersed hand (Phase x Immersion 
interaction, F (2,28) = 8.57, p < .001; Figure 3A-B). Neither the Pain Group nor the Drug 
condition influenced thermal hyperalgesia at the burnt sites (none of the effects that involved 
these factors achieved statistical significance). 
Unburnt sites. Although the Drug condition had no consistent effect on the HPT at 
unburnt sites (Figure 3C-D), Drug effects differed among the pain tolerance subgroups 
(interaction between Pain Group, Drug, Immersion and Phase (pre-immersion to second post-
immersion measurement), F (2,29) = 5.27, p < .05). In pain-tolerant participants, naloxone 
blocked thermal hypoalgesia at the unburnt site in the non-immersed hand (Figure 4A). 
However, in the mid-range group, naloxone evoked thermal hypoalgesia at unburnt sites in 
both hands (Figure 4B). In pain-intolerant participants, naloxone blocked thermal hypoalgesia 
after the immersions only at an unburnt site in the immersed hand (Figure 4C).  
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DISCUSSION 
The effect of the immersions on the HPT  
The primary aim of this study was to determine whether subcutaneous injection of 
naloxone at a site of burn injury in the hand would modify thermal hyperalgesia locally after 
the hand was immersed repeatedly in painfully cold water. Sensitivity to heat decreased at the 
burnt site in the immersed hand after the immersions, but was unaffected by opioid receptor 
blockade.  
The mechanism of this reduction in sensitivity to heat is uncertain. To minimize the 
possibility that cold-induced nerve conduction block would influence sensitivity to heat after 
the immersions, the hand was re-warmed to pre-immersion temperatures before measuring the 
HPT. Myelinated fibres appear to be more susceptible to cold-induced conduction block than 
non-myelinated fibres.15 Washington et al.37 reported that conduction velocity along 
myelinated fibres was unaltered after the hand was re-warmed following repeated cold-water 
immersions. Given that non-myelinated fibres contribute to heat-pain perception in 
humans,17,40 an effect of cold-induced conduction block on the HPT after the hand was re-
warmed seems unlikely. Moreover, the progressive decrease in sensitivity to heat in the 
immersed hand after the immersions is not consistent with a cold-induced nerve conduction 
block, which should dissipate rather than intensify over time.  
Nevertheless, a local effect of the immersions appeared to contribute to hypoalgesia, 
because it developed sooner at the burn site in the immersed hand than in the non-immersed 
hand. Indeed, sensitivity to heat increased transiently after the immersions in the non-
immersed hand. This finding was unexpected, because processes such as diffuse noxious 
inhibitory controls generally suppress painful sensations after intense noxious stimulation.36 
The mechanism of contralateral hyperalgesia after the immersions requires further 
investigation. 
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Individual differences in tolerance of cold-pain 
Willingness to tolerate cold-evoked pain varied greatly within our sample of healthy 
young adults. This variation was unrelated to age, sex, or heat-pain thresholds before the 
immersions. Geisser and colleagues16 found that pain-intolerant individuals reported more 
unhelpful coping strategies (catastrophizing, praying, and hoping), and fewer helpful coping 
strategies (coping self-statements and ignoring the pain) than pain-tolerant participants. In 
addition, pain-intolerant individuals considered that they had less control over pain and their 
ability to reduce it than pain-tolerant individuals. Similarly, Chen et al.8 reported that anxiety 
and general fearfulness were associated with pain intensity ratings in pain-intolerant but not 
pain-tolerant participants. Although the generality of the pain tolerance dichotomy has been 
questioned,21 individual differences in pain sensitivity and tolerance are associated with 
biological markers.12,18 For example, genetic variations that regulate levels of catecholamine-
O-methytransferase12 may influence pain sensitivity and opioid activity in pain-tolerant 
people. In addition, activity in cerebral cortical regions that process painful sensations and 
that coordinate emotional responses to pain is greater in pain-sensitive than pain-insensitive 
individuals,9 possibly due to inhibitory effects of opioid release in pain-insensitive people.6  
In the present study, naloxone augmented cold-induced pain in the pain-tolerant group. In 
particular, pain tolerance was lower and pain ratings were higher in the naloxone than saline 
condition during the third and fourth immersion trials, and pain began sooner in the naloxone 
than the saline condition in the sixth trial. Why the onset of the hyperalgesic effects of 
naloxone differed across the different pain measures is unclear; however, it seems reasonable 
to assume that noxious stimulation would trigger opioid release more readily above than 
below the pain threshold. If so, opioid effects on the pain threshold would, by necessity, lag 
behind opioid effects on pain tolerance and pain ratings. In addition, psychological factors 
(e.g., fear of pain or low self efficacy) that provoke opioid release – and which may then be 
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modified by this release – might have a greater influence on pain tolerance and ratings than on 
pain thresholds. In any event, the findings suggest that individual differences in evoked opioid 
release during repeated painful stimulation contribute to individual differences in pain 
tolerance. 
After the immersions, naloxone antagonized decreases in heat-pain sensitivity in pain-
tolerant participants at an unburnt site in the non-immersed hand (i.e., at some distance from 
the site of injection, implying that naloxone had entered the systemic circulation). In animal 
studies, central opioid-mediated analgesia develops during prolonged stress,10 particularly 
when the stress is inescapable.5,19 Similarly, experimentally induced stress evokes opioid 
analgesia in healthy humans,3,20,41-43 and may have induced a similar response during lengthy 
immersions in the present study. Alternatively, naloxone may have acted peripherally on 
opioid receptors in the non-immersed hand. Why this was limited to the unburnt site in the 
non-immersed hand is unclear; one possibility is that hyperalgesia due to the burn injury, 
and/or hypoalgesia after the immersions, masked the modulatory effect of opioid release.  
Naloxone produced quite different effects at the unburnt site in the non-immersed hand in 
participants who tolerated medium-length immersions. In particular, naloxone facilitated 
thermal hypoalgesia, implying that naloxone decreased or opioids increased sensitivity to 
noxious heat. It is interesting to note the parallels between our findings and those of 
Buchsbaum et al.,6 who reported that naloxone inhibited shock-induced pain in pain-sensitive 
individuals but enhanced shock-induced pain in pain-insensitive individuals. Low levels of 
opiate drugs such as morphine induce hyperalgesia;22 thus, it is tempting to speculate that 
minor opioid release in the central nervous system augmented thermal hyperalgesia after 
medium-length immersions. Alternatively, systemic release of opioids may have indirectly 
sensitized peripheral nerves via inflammatory mechanisms.13,14,23,25  
Naloxone also blocked a decrease in sensitivity to heat in pain-intolerant participants at 
  
- 13 - 
the unburnt site in the immersed hand after the immersions. As this was limited to the 
immersed hand, this finding is consistent with local opioid analgesia. In animal studies, 
peripheral opioid analgesia during cold-water swims is mediated by opioid receptors on the 
peripheral terminals of sensory nerves which are stimulated by β-endorphin.26,28,31,32 The β-
endorphin appears to be released from immune cells by corticotrophin-releasing factor,30 
interleukin-1,7 and noradrenaline.4  
Methodological issues 
Immersion duration was controlled by the participants rather than the experimenter, and 
may reflect a stable individual trait that moderates sensitivity to pain. Thus, further studies 
that systematically vary the immersion duration are required to determine whether immersion 
duration or individual differences in pain tolerance affect opioid activity.  
We expected that burn-induced inflammation would intensify local opioid analgesia due 
to an accumulation of immune cells at the site of burn injury. However, for unknown reasons, 
effects of naloxone were weaker at burnt than unburnt sites. One potential explanation is that 
local vascular or inflammatory responses during the immersions increased accessibility to 
peripheral opioid receptors at unburnt sites. Alternatively, the inflammatory effect of the burn 
might have spread to adjacent skin in the immersed hand, or the burn injury may not have 
been severe enough to result in local accumulation of immune cells.  
Based on our previous work,29 we expected that effects of naloxone would be greatest at 
the site of injection. However, the present findings suggest that naloxone acted at a distance to 
augment (after medium-length immersions) or block (after lengthy immersions) thermal 
hypoalgesia contralateral to the site of injection. Studies involving injection of naloxone in the 
non-immersed hand may help to further distinguish between the effects of local versus 
systemic or central opioid release on sensitivity to heat-pain in this experimental paradigm. 
The effects of systemic and local opioid release on other nociceptive modalities (e.g., pain to 
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pressure, cold, and punctuate stimulation) should also be explored. 
Finally, investigation of the effects of naloxone in relation to cold-pain tolerance should 
be considered exploratory in the present study, because the sample size was small. In 
particular, findings in pain-intolerant subjects must be treated with caution because of the 
small number of participants in this group. Groups were defined post hoc at noticeable, but 
perhaps serendipitous, breaks in the distribution of immersion duration scores in the saline 
session. Cold-pain tolerance remained reasonably stable across sessions in the present study, 
particularly during the first immersion (Figure 2D-F), suggesting that cold-pain tolerance is a 
stable individual trait. However, the group structure identified in this study needs to be 
confirmed in a larger sample. 
Conclusions 
Cold-water immersions induced complex opioid-mediated effects on nociceptive 
processing. Systemic or central opioid release inhibited cold-evoked pain during lengthy 
immersions, and inhibited sensitivity to heat at an unburnt site in the non-immersed hand after 
the immersions. However, in participants who tolerated medium-length immersions, systemic 
or central opioid release appeared to augment sensitivity to heat after the immersions. This 
hyperalgesic response may have overshadowed inhibitory effects of local opioid release on 
sensitivity to heat, which were detected only after brief immersions. 
Further investigation of the effects identified in the present research may help to clarify 
the triggers and source of individual differences in peripheral and central opioid anti-
nociceptive mechanisms. This could have implications for developing more effective 
treatment strategies for pain control at sites of inflammation and injury.   
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Table 1 
Sequence of procedures 
1. Burn injury over the first dorsal interosseous muscle of each hand 
2. Heat-pain threshold (HPT) measured 30 min later at each burn site and at an 
untreated site on each hand 
3.  Double-blind subcutaneous injection of naloxone or saline into one burn site 
4.  HPT measured 5 min later at all four sites 
5.  Repeated immersion of the injected hand in cold water 
6. Hand re-warmed for 3-5 min to pre-immersion temperature 
7. HPT measured at both sites in both hands straight after the hand was re-warmed, 
and again 5 min later 
8. Procedures repeated 4-7 days later with subcutaneous injection of the agent 
(naloxone or saline) not administered in the first session 
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Table 2 
Skin temperature (oC + SEM) before and after the immersions 
 Naloxone Session Saline Session 
Site Before After Before After 
Burnt immersed 31.1 + .3 31.2 + .3 31.3 + .4 31.2 + .3 
Burnt unimmersed 31.5 + .3 31.4 + .3 31.1 + .3 31.3 + .4 
Unburnt immersed 30.9 + .3 30.7 + .3 30.6 + .3 30.4 + .2 
Unburnt unimmersed 30.9 + .3 30.7 + .4 30.9 + .4 31.0 + .4 
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Table 3 
Sex, age, and mean heat pain thresholds (HPT) in burnt and unburnt skin before the cold-
water immersions, in groups differing in cold-pain tolerance 
 Pain-Intolerant Mid-Range Pain-Tolerant 
Males (N) 3 8 6 
Females (N) 4 8 3 
Age (years) + SEM 19.9 + 1.3 21.6 + 1.2 20.7 + 2.4 
HPT burnt skin (oC) + SEM 40.6 + 0.8 40.9 + 0.5 41.7 + 0.7 
HPT unburnt skin (oC) + SEM 42.0 + 1.0 42.2 + 0.7 43.5 + 0.9 
Note: none of the differences among groups was statistically significant.
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Figure captions 
Figure 1.  Mean immersion duration (in s) in all 32 participants during the saline session 
plotted against mean immersion duration during the naloxone session (Panel A), and plotted 
against the difference in immersion duration during the two sessions (Panel B). Note that the 
mean immersion duration was 180 s during both sessions in three of the participants. The 
dotted lines in Panel B represent the cut-off points for the pain-intolerant group (mean 
duration of immersion in the saline session less than 35 s), the mid-range group (range 57-128 
s), and the pain-tolerant group (range 142-180 s). 
Figure 2. Pain threshold (Panels A-C), pain tolerance (Panels D-F), and pain ratings (Panels 
G-I) during the first six trials of cold-water immersion for the saline (open symbols, dotted 
lines) and naloxone (closed symbols, unbroken lines) sessions. In the pain-tolerant group, 
pain started sooner, tolerance was lower, and pain ratings were greater during certain trials of 
the naloxone session than the saline session (* p < 0.05). Error bars show ± 1 SEM. 
Figure 3. Mean heat-pain thresholds (in degrees C) in the saline (open symbols, dotted lines) 
and naloxone (closed symbols, unbroken lines) sessions at the burnt and unburnt sites on the 
immersed and non-immersed hands (Panels A-D). The HPT increased from pre-immersion 
levels at the burnt site in the immersed hand (* p < 0.01) but not at other sites. However, the 
HPT sometimes differed between consecutive measurement points (# p < 0.05). Despite the 
increase in the HPT at the burnt site after the immersions, the HPT remained lower at burnt 
(A,B) than unburnt sites (C,D) for the remainder of the experiment (p < .01 at all sites at 
every measurement point). Error bars show ± 1 SEM (n = 32).  
Figure 4. Mean change in heat-pain threshold (in degrees C) from pre-immersion to the 
second post-immersion measure at unburnt sites in the immersed and non-immersed hands in 
the saline (open bars) and naloxone sessions (filled bars) in pain-tolerant (Panel A), mid-range 
(Panel B) and pain-intolerant participants (Panel C).  A positive score indicates thermal 
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hypoalgesia whereas a negative score indicates thermal hyperalgesia. Naloxone blocked 
thermal hypoalgesia in the non-immersed hand of pain-tolerant participants (* difference 
between the saline and naloxone sessions, p < .05, Wilcoxon matched-pairs signed ranks two-
tailed test), but appeared to mediate thermal hypoalgesia in participants who were neither 
pain-tolerant nor intolerant (* p < .05, Wilcoxon two-tailed test). In pain-intolerant 
participants, naloxone blocked thermal hypoalgesia in the immersed hand but not the non-
immersed hand, consistent with local opioid analgesia (# p < .05, Wilcoxon one-tailed test). 
 
  
- 26 - 
0 60 120 180
0
60
120
180
A.
Saline
N
al
ox
on
e
0 60 120 180
-150
0
150
B.
Saline
Sa
lin
e 
- N
al
ox
on
e
Mean Tolerance (s)
  
- 27 - 
A. Pain-Intolerant (N = 7)
1 2 3 4 5 6
0
50
100
150
TRIAL NUMBER
PA
IN
 T
H
R
ES
H
O
LD
 (s
)
B. Mid-Range (N = 16)
1 2 3 4 5 6
0
50
100
150
TRIAL NUMBER
PA
IN
 T
H
R
ES
H
O
LD
 (s
)
C. Pain-Tolerant (N = 9)
1 2 3 4 5 6
0
50
100
150
*
TRIAL NUMBER
PA
IN
 T
H
R
ES
H
O
LD
 (s
)
D. Pain-Intolerant (N = 7)
1 2 3 4 5 6
0
50
100
150
200
TRIAL NUMBER
PA
IN
 T
O
LE
R
AN
C
E 
(s
)
E. Mid-Range (N = 16)
1 2 3 4 5 6
0
50
100
150
200
TRIAL NUMBER
PA
IN
 T
O
LE
R
AN
C
E 
(s
)
F. Pain-Tolerant (N = 9)
1 2 3 4 5 6
0
50
100
150
200
* *
*
TRIAL NUMBER
PA
IN
 T
O
LE
R
AN
C
E 
(s
)
G. Pain-Intolerant (N = 7)
1 2 3 4 5 6
0.0
2.5
5.0
7.5
10.0
TRIAL NUMBER
P
A
IN
 R
A
TI
N
G
 (0
-1
0)
H. Mid-Range (N = 16)
1 2 3 4 5 6
0.0
2.5
5.0
7.5
10.0
TRIAL NUMBER
PA
IN
 R
AT
IN
G
 (0
-1
0)
I. Pain-Tolerant (N = 9)
1 2 3 4 5 6
0.0
2.5
5.0
7.5
10.0
* *
TRIAL NUMBER
PA
IN
 R
AT
IN
G
 (0
-1
0)
 
  
- 28 - 
Burnt Site,
Immersed Hand
40
41
42
43
44
Pre                 1                      2
Immersion          Post Immersion
A.
# *
*
H
PT
 (
o C
 )
Burnt Site,
Non-Immersed Hand
40
41
42
43
44
Pre                  1                      2
Immersion           Post Immersion
B.
#
#
H
PT
 (
o C
 )
Unburnt Site,
Immersed Hand
40
41
42
43
44
Pre                  1                      2
Immersion         Post Immersion
C.
#
H
PT
 (
o C
 )
Unburnt Site,
Non-Immersed Hand
40
41
42
43
44
Pre                  1                      2
Immersion           Post Immersion
D.
#
#
H
PT
 (
o C
 )
  
- 29 - 
Pain-Intolerant (N = 7)
-1.0
-0.5
0.0
0.5
1.0
Immersed         Non-Immersed
Hand                      Hand
C.
#
Mid-Range (N = 16)
-1.0
-0.5
0.0
0.5
1.0
Immersed         Non-Immersed
Hand                      Hand
B.
*
*
Pain-Tolerant (N = 9)
-1.0
-0.5
0.0
0.5
1.0
Immersed         Non-Immersed
Hand                      Hand
A.
*
hypoalgesia
hyperalgesia
C
ha
ng
e 
in
 H
PT
 (o
C
)
af
te
r t
he
 Im
m
er
si
on
s
 
